Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis

Colon cancer is still the third most common cancer which has a high mortality but low five-year survival rate. Novel tyrosine kinase inhibitors (TKI) such as pazopanib become effective antineoplastic agents that show promising clinical activity in a variety of carcinoma, including colon cancer. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lingling, Wang, Huanan, Li, Wei, Zhong, Juchang, Yu, Rongcheng, Huang, Xinfeng, Wang, Honghui, Tan, Zhikai, Wang, Jiangang, Zhang, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356882/
https://www.ncbi.nlm.nih.gov/pubmed/27924057
http://dx.doi.org/10.18632/oncotarget.13753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356882/
https://www.ncbi.nlm.nih.gov/pubmed/27924057
http://dx.doi.org/10.18632/oncotarget.13753

Ejemplares similares